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Modification of cytotoxic drug resistance by non-immuno-suppressive
cyclosporins
P.R. Twentyman
MRC Clinical Oncology and Radiotherapeutics Unit, Hills Road, Cambridge CB2 2QH, UK.
Summary We have examined the ability of a series of non- or minimally-immunosuppressive analogues of
cyclosporin A to modify cytotoxic drug resistance in vitro. The series includes both cyclosporins derived from
naturally-occurring compounds and synthetic cyclosporins. In contrast to our previous findings, we now
report that several of these analogues are highly effective modifiers of resistance to adriamycin and vincristine
in a multidrug resistant subline of the human small cell lung cancer cell line NCI-H69. Two of the analogues
(W8-032 and B3-243) maintain considerable activity in the dose range 1-2pgml-1 whereas little activity
remains for cyclosporin A when the dose is reduced to this level. B3-243, however, in contrast to cyclosporin
A and W8-032, does itself show growth inhibitory effects in this dose range. Possible clinical trial of these
cyclosporins as resistance modifiers will depend upon their in vivo toxicology and pharmacokinetic properties.
Pleiotropic drug resistance in model systems may be partially
overcome by the use of additional chemical agents termed
'resistance modifiers'. The prototype agent is the calcium
transport blocker, verapamil (Tsuruo et al., 1981, 1982;
Slater et al., 1982; Twentyman et al., 1986a). Recently, it has
been shown by Slater et al. (1986a,b) that the immuno-
suppressive drug, cyclosporin A acts as a modifier of resis-
tance to daunorubicin and vincristine (VCR) in Ehrlich
ascites carcinoma in vivo and in human acute lymphatic
leukaemia in vitro. Our studies of cyclosporin A in a highly
multi-drug resistant variant of a human small cell lung
cancer cell line (Twentyman et al., 1987) confirmed that the
agent could considerably reduce the degree of resistance to
both adriamycin (ADM) and VCR. Three naturally-
occurring analogues were also studied and a close correlation
was seen between the immunosuppressive properties of the
analogues and their ability to modify drug resistance. In an
attempt to further clarify this relationship, we have now
studied an additional series of cyclosporin analogues and the
results of these studies are the subject of this paper.
Materials and methods
Cells and culture conditions
The cells used in this study were of the human small cell
lung cancer line NCI-H69 and a highly multi-drug resistant
subline (e.g. >100 fold resistance to ADM) derived in this
laboratory (Twentyman et al., 1986a). The parent cells are
designated H69/P and the resistant subline H69/LX4. The
cells are routinely grown in RPMI 1640 medium (Gibco
Biocult) supplemented with 10% foetal calf serum (Seralab
Ltd) together with penicillin and streptomycin. The cells
grow as free-floating aggregates and the population doubling
times of H69/P and H69/LX4 in the absence of drug are 39
(95% CL =33-47) and 54 (46-64)h respectively. Subline
H69/LX4 is routinely maintained in the presence of
0.4pgml-1 ADM but cells were washed free of drug and
kept in drug-free medium for 2-3 days before use in experi-
ments. Growing cultures of cells were mechanically disag-
gregated for experimental use by repeated pipetting. This
resulted in a suspension consisting of single cells and small
aggregates of up to 10 cells. From this mechanically-
disaggregated suspension an aliquot was taken and formally
disaggregated using trypsin and versene (Twentyman et al.,
1986b). A haemocytometer count was then carried out and
the figure obtained was used as an estimate of the cell
concentration in the mechanically-disaggregated suspension
Received 18 September 1987; and in revised form, 4 January 1988.
which was actually used for setting up experiments. This
procedure was considered necessary as enzymatic reduction
of H69 cultures to a single cell suspension results in a
prolonged 'lag' in subsequent growth whereas mechanical
disaggregation appears to be much less growth inhibitory.
Response assay
To determine the drug response of H69/P and LX4 cells, we
used a tetrazolium dye reduction assay (MTT) carried out on
96-well microtitre plates (Falcon Plastics). The assay is based
on that originally described by Mosmann (1983) but using
DMSO as the solvent (Alley et al., 1986; Carmichael et al.,
1987). We have previously studied a number of variables
involved in the optimal use of this assay (Twentyman &
Luscombe, 1987). Evidence that the assay may be validly
used to assess the response of human lung cancer cells to
cytotoxic drugs has recently been published (Cole, 1986;
Carmichael et al., 1987).
The assay is based on the ability of viable cells to reduce
a yellow-coloured soluble tetrazolium salt, 3-4, 5
dimethylthiazol-2, 5 diphenyl tetrazolium bromide (MTT) to
an insoluble, purple-coloured formazan precipitate. After
aspiration of most of the medium, the formazan may be
dissolved in DMSO and the optical density measured at
550 nm using an ELISA plate reader (Twentyman &
Luscombe, 1987). The assay represents a rapid and semi-
automatic method of quantifying the number of viable
cells/well following a period of growth in the presence or
absence of various drugs or drug combinations.
For the experiments described in this paper, 96-well plates
were set up with between 5 x 103 and 104 (H69/P) or
between 104 and 2 x104 (H69/LX4) cells per well in 200p1
medium. After a period of - 2h incubation (to allow
equilibration of medium pH, etc), cyclosporins (or solvent
controls) were added to each well in a volume of IOpl. After
2 more hours of incubation, cytotoxic drugs (ADM or VCR)
were added in 20pl. To determine each dose-response curve
we used one control well and seven 2-fold dilutions of
cytotoxic drug. Within any single experiment, 3 or 4 repli-
cates of each drug response point were carried out. Plates
were then incubated for a period of 6 days in a gassing
incubator (8% C02, 92% air) at 37°C. (This period was
chosen as the time for control H69/P cells to have increased
in number by 10 fold and be approaching the end of the
exponential growth phase (Twentyman et al., 1986b)).
At the end of the incubation period, 20pl of a 5mgml 1
solution of MTT (Sigma) in PBS was added to each well and
the plates returned to the incubator for a further 5h. After
this, the plates were centrifuged for 5min at 400g in order to
pack the floating cell aggregates to the bottom of the wells.
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The bulk of the medium was removed from each well using a
Pasteur pipette connected to a vacuum line, leaving 10-20p1
medium per well. To each well was then added 200p1
DMSO and the plates were agitated on a plate-shaker for
5min. Optical densities were then read at a wavelength of
540nm on a 'Titertek Multiskan' ELISA plate reader.
Drugs
Cyclosporin A and 6 analogues were kindly supplied by
Sandoz (Basel) Ltd. The structures of those compounds are
shown in Figure 1 and their immunosuppressive properties in
Table I. The cyclosporins were initially dissolved in absolute
ethanol at a concentration of 5mgml- and then diluted in
medium before addition to wells. The final concentration of
ethanol in the wells was 0.1% and control experiments
Cyclosporin A
showed that this neither affects cell growth or modifies the
response to ADM or VCR in our system. In one preliminary
experiment, cyclosporins were (mistakenly) added to wells in
a final ethanol concentration of 1.0% but again we were able
to show that this did not affect cell growth or ADM
response. Upon dilution of the alcoholic solutions into
medium, a fine precipitation of the cyclosporins was seen to
occur. We were unwilling to use agents such as Tween 80 in
order to prevent this because of the possibility that such
membrane-active agents may themselves modify drug-
resistance. It was considered that protein-binding of the
cyclosporins would enable the drug to be presented to the
cells in an acceptable state despite the apparent precipitation.
Cytotoxic drugs adriamycin (ADM, Pharmitalia) and
vincristine (VCR, Eli Lilley) were initially dissolved in sterile
water and solutions of 500pgml-1 stored either at -20°C
(ADM) or +4°C (VCR). Dilutions for use in experiments
were prepared immediately before use.
2 3 4
Cg - - Abu - - Sar - MeLeu
1 1 MeVal Val 5
MeLeu - MeLeu Z- Ala *- Ala -- MeLeu
10 9 8 7 6
CsA = cyclosporin A
W8-032 = (Me lie1") CsA
W4-717 = (O-tBu)-D-Ser8 CsA
B3-243 = (0-acetyl) C91 CsA
WO-039 = (MeAla6) CsA
B3-665 (0-acetyl) Thr2 CsA
W8-582 (L-Pro3) CsA
Figure 1 Amino acid sequence of cyclosporins. Redrawn from
von Wartburg and Traber (1986), C. is a hitherto unknown
amino acid =[2S, 3R, 4R, 6E]-3-hydroxy-4-methyl-2-methyl
amino-6-octenoic acid; Abu=L-a-amino butyric acid; MeVal=
N-methyl-L-valine; MeLeu=N-methyl-L-leucine.
Results
We first of all studied the relationship in the MTT assay
between the number of cells plated and the final optical
density (OD) 6 days later. A typical set of results is shown in
Figure 2. It may be seen that the relationship is approxi-
mately linear for both H69/P and H69/LX4 up to a cell
number plated of 104 (OD= 1.8) (H69/P) or 2 x 104
(OD=1.4) (H69/LX4) with both lines passing through the
origin. These data enabled us to select the optimal number
of cells to plate in subsequent experiments. A typical set of
dose-response data obtained using the MTT assay is shown
in Figure 3. For each dose-response curve an ID50 can be
read as the drug dose required to reduce to final optical
density to 50% of the control value. There is a very close
agreement between several of the curves shown in Figure 3
and the corresponding curves which we have previously
published using a 'total cell count assay' (Twentyman et al.,
1987) for fractional optical densities above 0.2-0.3. At higher
drug doses, the MTT curves tend to show a plateau not seen
when using total cell count as the endpoint. We believe that
this plateau represents an artefact of the MTT assay and
hence we have used the ID50 to quantitate drug sensitivity
using MTT whereas we previously used the ID80.
Table I Immunosuppressive properties ofcyclosporinsa
Immunosuppressive activity
In vitro'
Cyclosporin Originb (IC509gmI-) In vivod
Cyclosporin A N <0.04 highly positive
W8-032 S 0.4-1.0 negative
W4-717 S .5.0 not tested
B3-243 D . 5.0 negative
W0-039 S 0.3-3.0 negative
B3-665 D 1.0-2.0 negative
W8-582 S 1.0-5.0 not tested
aData are personal communications from J. Borel and R.
Wenger of Sandoz (Basel) Ltd; bN =naturally occurring,
D=derivated from a naturally occurring compound, S=synthe-
tic analogue; cThe following classical assays were used for deter-
mining the IC50 in vitro: mitogen activation (e.g. Con A) of
murine spleen cells, mixed lymphocyte reaction, cell-mediated
lympholysis, Mishell-Dutton (PFC) assay, all with murine spleen
cells, cytotoxicity to P-815 mastocytoma cells.; dThe in vivo
models used were: antibody formation as measured by the
plaque-forming assay (PFC) in mice and rats, localised graft-
versus-host reaction (popliteal lymph node weight) in rats,
delayed-type hypersensitivity reaction to oxazolone or with T-cell
clones in mice, adjuvant arthritis in rats, renal allograft in rats.
NB. Some compounds have not been tested in every assay.
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Figure 2 Relationship between optical density measured in the
MTT assay at day 6 and the number of cells inoculated at day 0
into 96 well microtitre plates. Solid circles - H69/P, open circles
- H69/LX4. Points are mean values of 4 replicate wells and error
bars show the standard deviation. No error bars are shown when
these are smaller than the dimensions of the symbol.
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Figure 3 Relationship between optical density in the MTT assay
and the dose of adriamycin present during 6 days of growth.
Closed symbols - H69/P, open symbols - H69/LX4. Circles and
solid lines - ADM alone, triangles and dashed lines -
ADM+cyclosporin A (2 gml-1), squares and dotted lines -
ADM+B3-243 (lpgml-1).
In a preliminary experiment, the effect of each of the
cyclosporins to inhibit cell growth and modify ADM sensi-
tivity was studied at the very high dose level of 50pgml-1.
Three of the cyclosporins (CsA, B3-243 and WO-039)
produced essentially total inhibition of cell growth in both
H69/P and H69/LX4 at this concentration. Two agents (W8-
032 and W4-717) inhibited the growth of H69/P by -70%
whereas W8-582 and B3-665 inhibited growth by 44% and
35% respectively. These latter 4 agents all produced rather
less growth inhibition in H69/LX4 than in H69/P (in terms
of % of final optical density). Where it was possible to
assess sensitisation to ADM (for W8-032, W4-717, B3-665
and W8-582) all of the agents were seen to produce
considerably more sensitisation in resistant (H69/LX4) than
in control (H69/P) cells.
The effects in combination with ADM of the cyclosporins
at dose of 5pgml-1 were then studied. Results are shown in
Table II. It may be seen that the sensitisation ratios
(SR-ID50 in absence of cyclosporin
ID50 in presence of cyclosporinn
in the parent cells are all 2.1 or less. In the resistant cells,
however, very much higher values of SR were obtained
with values of 10 or greater being obtained for each agent
except B3-665. At 5pgml-1, only B3-243 was itself growth
inhibitory (-50% of control). The ID50s for CsA and W8-
032 alone were subsequently determined to be >10pgml-1.
Four of the cyclosporins were then studied at further
reduced dose levels in combination with ADM. Results of
two independent experiments are shown in Table III and the
sensitisation ratios for the resistant cells (H69/LX4) are
shown graphically in Figure 4. It is seen that, whereas most
Table II Effects of cyclosporins at 5pgml-I on response of H69/P
and H69/LX4 cells to adriamycin
H69/P H69/LX4
ADM ADM
Cyclosporin ID50(ugml19 ) SR' ID50(pgml-) SR'
0.0084 1.0 1.00 1.0
CsA 0.0072 1.2 <0.05 >20
W8-032 0.0040 2.1 <0.05 >20
W4-717 0.0071 1.2 0.07 14.3
B3-243 0.0085 1.0 <0.05 >20
WO-039 0.0066 1.3 0.10 10.0
B3-665 0.0070 1.2 0.40 2.5
W8-582 0.0055 1.5 0.10 10.0
ID50 in absence ofcyclosporin aSR=Sensitisation Ratio= 50 ID50 in presence of cyclosporin
of the sensitisation by CsA is lost when the dose is reduced
to 1 ,ugml -1 (SR values=2.0, 3.8), much higher SRs are
maintained by W8-032 and B3-243 at this dose level (9.1, 9.1
and 21.1, 25.6). Furthermore, clear sensitisation of the
resistant cells by B3-243 is still seen at a dose of 0.5pgml-1.
There was again some growth inhibition by B3-243 alone.
This was rather variable but averaged -40% at 2pgml-1
and -20% at 1 pgml-1. The extent was, however, similar in
parent and resistant cells and does not, therefore, appear to
be directly related to resistance modification.
A similar experiment was carried out in which these 4
cyclosporins were combined with VCR. Results are shown in
Table IV. It is again seen that W8-032 and B3-243 maintain
activity to lower dose levels than does CsA, producing
sensitisation ratios of 13.1 and 25.0 respectively at 1 pgml1
compared with 3.9 for CsA.
Table II Effects of cyclosporins at ..2Mgml 1 on response of
H69/P and H69/LX4 to adriamycin
H69/P H69/LX4
Dose ADM ADM
Cyclosporin (pgml-1) ID50(Ugml- ) SR' ID50(pgml9 Ml) SRa
0.0088 1.0 2.0 1.0
0.0095 1.0 1.0 1.0
2 0.0048 1.8 0.40 5.0
0.0060 1.6 0.073 13.7
CsA 1 0.0047 1.9 1.0 2.0
0.0066 1.4 0.26 3.8
0.5 0.0045 2.0 1.5 1.3
0.0060 1.6 0.40 2.5
2 0.0056 1.6 0.048 41.6
0.0065 1.4 0.044 22.7
1 0.0072 1.2 0.22 9.1
0.0070 1.4 0.11 9.1
W8-032 0.5 0.0072 1.2 0.60 3.3
0.0065 1.4 0.52 1.9
0.25 - _ _ _
0.0070 1.4 0.80 1.3
2 0.0068 1.3 0.35 5.7
0.0090 1.1 0.15 6.7
WO-039 1 0.011 0.8 1.10 1.8
0.0078 1.2 0.32 3.1
0.5 0.0095 0.9 1.50 1.3
0.0090 1.1 0.52 1.9
2 0.0120 0.7 0.048 41.7
0.0078 1.2 0.015 66.7
1 0.0120 0.7 0.095 21.1
0.0088 1.1 0.039 25.6
B3-243 0.5 0.0130 0.7 0.68 2.9
0.0080 1.2 0.14 7.1
0.25 - _ _ _
0.0086 1.1 0.62 1.6
Two different experiments are shown.
'SR=sensitisation ratio (see Table II).
Discussion
In our previous study (Twentyman et al., 1987), we found
that, in a series of naturally-occurring cyclosporins, there
was good agreement between the immunosuppressive
properties of these agents and their ability to act as
modifiers ofmulti-drug resistance. Cyclosporins A and G are
highly immunosuppressive (von Wartburg & Traber, 1986)
and were the most potent resistance modifiers whilst the
non-immunosuppressive cyclosporin H had little or no
resistance-modifying ability. Each of these analogues has
only a single amino acid change compared with CsA (von
Wartburg & Traber, 1986). In further studies of CsA,
however, we found that a concentration of 5pgmml1 was
-
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Figure 4 Relationship between sensitisation ratio (see Table II)
and dose of cyclosporins present during incubation of H69/LX4
cells with adriamycin. Results are taken from the two
experiments shown in Table III.
0 CsA
0 B3-243
A W8-032
A WO-039
Table IV Effects of cyclosporins at <2pgml-P on response of
H69/P and H69/LX4 to vincristine
H69/P H69/LX4
Dose VCR VCR
Cyclosporin (gml-1) ID50(ugm1-1) SR' ID50(Ugml-') SR'
0.0011 1.0 0.55 1.0
2 0.00055 2.0 0.017 32.3
CsA 1 0.00062 1.8 0.14 3.9
0.5 0.00058 1.9 0.21 2.6
2 0.00069 1.6 0.0033 167.0
1 0.00080 1.4 0.042 13.1
W8-032 0.5 0.00090 1.2 0.15 3.7
0.25 0.00083 1.3 0.39 1.4
2 0.00056 2.0 0.090 6.1
WO-039 1 0.00075 1.5 0.36 1.5
0.5 0.00095 1.2 0.43 1.3
2 0.0011 1.0 0.011 50.0
1 0.00075 1.5 0.022 25.0
B3-243 0.5 0.00090 1.2 0.13 4.2
0.25 0.0010 1.1 0.26 2.1
'SR=sensitisation ratio (see Table H).
required for major reduction of ADM or VCR resistance
and most of the effect was lost if the dose were reduced to
2jugml-1 This is unfortunate in view of the fact that
plasma concentrations of CsA achievable clinically appears
to lie in the range of 1-2pgml1 (Kahan et al., 1983).
We now find, however, that several of the non- or
minimally-immunosuppressive cyclosporins investigated in
the present study are not only highly effective resistance
modifiers at a dose of 5jMgml- ' but also retain more activity
at lower doses compared with CsA. In terms of in vitro
immunosuppressive activity (see Table I), compounds W4-
717 and B3-243 are at least 2 orders of magnitude less active
than CsA and neither shows any in vivo immunosuppressive
activity. In contrast, however, W4-717 shows considerable
ability to sensitise H69/LX4 cells to ADM and B3-243 is the
most active of all the compounds studied in this regard
(Table III & Figure 4). Although the effects of these resis-
tance modifiers are much greater in LX4 cells, there is
often a small degree of sensitisation in the parent H69 cells
also. This is clearly a fact which must be borne in mind
when considering possible increased normal tissue toxicity by
drugs such as ADM when combined with cyclosporins.
Furthermore, it is clear that these cyclosporins can be
growth-inhibitory on their own. A study by Saydjari et al.
(1986) has previously found growth inhibition by CsA in a
hamster pancreatic carcinoma cell line. In the cells used in
the present study, B3-243 was more growth-inhibitory than
either CsA or W8-032. For these latter two agents, resis-
tance modification occurs at dose levels which are not in
themselves growth-inhibitory. Furthermore, growth-inhibitory
effects of B3-243 are similar in H69/P and H69/LX4 cells. It
would not therefore appear that there is a direct relationship
between the growth inhibition by a given cyclosporin in a cell
line and its ability to act as a resistance modifier in that
line. Nevertheless, the relative growth-inhibitory properties
of different CsA analogues will be an important factor in
considering their relative potential merits as resistance
modifiers.
The studies described in this paper demonstrate that the
immunosuppressive properties and cytotoxic drug resistance
modification abilities of cyclosporins can be dissociated.
Hence it would seem that the biochemical mechanism of
action of cyclosporins in carrying out these two functions
must differ. It is not possible to identify on the basis of
the results presented in this paper and our previously pub-
lished data (Twentyman et al., 1987) the structure/activity
requirements for the cyclosporins either in terms of
immunosuppression or resistance modification. However,
studies of the immunosuppressive activity of a wider range of
natural analogues (von Wartburg & Traber, 1986) led to the
conclusion that an intact Cg amino acid at position 1 was
required. In addition, changes at other positions which
resulted in drastic distortion of the ring conformation led to
reduction or loss of immunosuppressive activity. Clearly the
modification of Cg in position 1 which occurs in B3-243 is
incompatible with immunosuppression but perfectly com-
patible with resistance modification. The compound W8-582
is the only compound in our series which has major
distortion of the ring conformation. The limited data for this
agent (Table II) indicate that this does not abolish the
resistance modification property. A systematic study of a
fuller range of analogues would, no doubt, enable firm
conclusions regarding the structure/activity relationship for
resistance modification to be established. Detailed studies
ofthe effects of CsA and B3-243 upon the cellular pharmaco-
kinetics of ADM and its analogues (currently in progress in
this laboratory) may help to elucidate the mechanism by
which resistance modification occurs.
Whether or not these new cyclosporin analogues are
candidates for clinical trial as resistance modifiers will
depend upon their toxicology and pharmacokinetic
properties in vivo. Investigation of such properties is
currently being undertaken with particular emphasis on
compound B3-243.
I am most grateful to Professor J.F. Borel and Dr R. Wenger of
Sandoz (Basel) for supply of cyclosporins and for information
regarding their chemical and biological properties. Excellent
technical assistance was provided by Ms Norma Fox.
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